News Column

BRIEF: Stereotaxis shares soar 14 percent after FDA approval

September 4, 2014

By Samantha Liss, St. Louis Post-Dispatch

Sept. 04--Shares of Stereotaxis rose 14 percent after receiving approval from the Food and Drug Administration for one of its cardiac instruments used by physicians.

Shares of Stereotaxis rose 39 cents to close at $3.24.

The FDA approved the Vdrive robotic navigation system with V-Loop variable loop catheter manipulator after the St. Louis-based medical technology company submitted an 510(k) premarket notification with the regulator in March. The equipment currently is in use in Europe.

Last year the company received approval for its first Vdrive product, the V-Sono ICE catheter manipulator, according to a statement from the company.

"This is another key step in our efforts to bring our full suite of Vdrive products to market in the U.S.," said William C. Mills, Stereotaxis Chief Executive, said in a statement.

Samantha Liss is a business reporter at the Post-Dispatch. Follow her on Twitter @samanthann and the business section @postdispatchbiz.


(c)2014 the St. Louis Post-Dispatch

Visit the St. Louis Post-Dispatch at

Distributed by MCT Information Services

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: St. Louis Post-Dispatch (MO)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters